Current methods for the reduction of blood-borne pathogens: A comprehensive literature review

Blood Transfusion

Volumn 11, Issue 3, 2013, Pages 343-348

  Picker, Susanne M ^a  

^a not available   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; FRESH FROZEN PLASMA; GLUTATHIONE; METHYLENE BLUE; PSORALEN; RIBOFLAVIN; THROMBOCYTE CONCENTRATE;

BLOOD TRANSFUSION; BLOODSTREAM INFECTION; DISEASE TRANSMISSION; ERYTHROCYTE CONCENTRATE; HUMAN; LEUKOCYTE TRANSFUSION; LIGHT; MEDICAL DEVICE; MEMBRANE FILTER; PHOTOSENSITIZATION; REVIEW; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ANIMAL; BLOOD COMPONENT THERAPY; BLOODBORNE BACTERIUM; DISINFECTION; PREVENTION AND CONTROL; PROCEDURES; RISK FACTOR; STANDARDS; TRENDS;

ANIMALS; BLOOD COMPONENT TRANSFUSION; BLOOD-BORNE PATHOGENS; DISEASE TRANSMISSION, INFECTIOUS; DISINFECTION; HUMANS; RISK FACTORS;

EID: 84882303170     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0218-12     Document Type: Review

References (65)

1. Heddle NM, Klama I, Singer J, et al. The role of the plasma from platelet concentrates in transfusion reactions. N Eng J Med 1994; 331: 625-8.
2. Klüter H, Bubel S, Kirchner H, Wilhelm D. Febrile and allergic transfusion reactions after the transfusion of white cell-poor platelet preparations. Transfusion 1999; 39: 1179-84.
3. Caspari G, Gerlich WH, Kiefel V, Gürtler L. Pathogen inactivation of cellular blood products - still plenty of reason to be careful. Transfus Med Hemother 2005; 32: 258-60.
4. Seifried E, Findhammer S, Roth WK. Status of NAT screening for HCV, HIV and HBV - experiences of the German Red Cross donation services. In Brown F, Seitz R, editors: Advances in Transfusion Safety. Basel: Dev Biol, Karger; 2002. vol. 108, pp. 23-7.
5. Hourfar MK, Jork C, Schottstedt V, et al; German Red Cross NAT Study Group. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008; 48: 1558-66.
6. Walther-Wenke G, Doerner R, Montag T, et al; Working party on Bacterial Safety in Transfusion Medicine of the Advisory Board of the German Ministry of Health (Arbeitskreis Blut), Berlin, Germany. Bacterial contamination of platelet concentrates prepared by different methods: results of standardized sterility testing in Germany. Vox Sang 2006; 90: 177-82.
7. Blajchman MA. Incidence and significance of the bacterial contamination of blood components. Dev Biol Basel, Karger 2002: 108; 59-67.
8. Ness P, Braine H, King K, et al. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001; 41: 857-61.
9. Perez P, Salmi LR, Folléa G, et al; BACTHEM Group; French Haemovigilance Network. Determinants of transfusionassociated bacterial contamination: results of the French BACTHEM case-control study. Transfusion 2001; 41: 862-72.
10. Brecher ME, Hay SN. The role of bacterial testing of cellular blood products in light of new pathogen inactivation technologies. Blood Ther Med 2003; 3: 49-55.
11. Klüter H. The struggle for safer blood: pathogen inactivation of cellular blood preparations. Blood Ther Med 2002; 2: 42-7.
12. Schrezenmeier H, Walther-Wenke G, Müller TH, et al. Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007; 47: 644-52.
13. Hei DJ, Grass J, Lin L, et al. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999; 39: 239-48.
14. Corash L, Lin L. Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease. Bone Marrow Transplant 2004; 33: 1-7.
15. Fast LD, Di Leone G, Marschner S. Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011; 51: 1397-404.
16. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang 2000; 78: 209-16.
17. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy-coats. Vox Sang 2000; 79: 206-14.
18. Picker SM, Speer R, Gathof BS. Functional characteristics of buffy-coat PLTs photochemically treated with amotosalen- HCl for pathogen inactivation. Transfusion 2004; 44: 320-9.
19. Janetzko K, Cazenave JP, Klüter H et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005; 45: 1443-52.
20. Klein HG, Anderson D, Bernardi MJ, et al. Pathogen inactivation: making decisions about new technologies. Report of a consensus conference. Transfusion 2007; 47: 2338-47.
21. Mintz PD, Bass NM, Petz LD, et al. Photochemically treated fresh frozen plasma for transfusion of patients with acquired coagulopathy of liver disease. Blood 2006; 107: 3753-60.
22. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy-coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood 2003; 101: 2426-33.
23. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial. Blood 2004; 104: 1534-41.
24. Cazenave JP, Isola H, Waller C, et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011; 51: 622-9.
25. Goodrich RP, Gilmour D, Hovenga N, Keil SD. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009; 49: 1205-16.
26. Marschner S, Goodrich RP. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother 2011; 38: 8-18.
27. Osselaer JC, Messe N, Hervig T, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2008; 48: 1061-71.
28. Cazenave JP, Waller C, Kientz D, et al. An active hemovigilance program characterizing the safety profile of 7483 transfusions with plasma components prepared with amotosalen and UVA photochemical treatment. Transfusion 2010; 50: 1210-9.
29. Benjamin RJ, McCullough J, Mintz PD, et al. Therapeutic efficacy and safety of red blood cells treated with a chemical process (S-303) for pathogen inactivation: a phase III clinical trial in cardiac surgery patients. Transfusion 2005; 45: 1739-49.
30. Zavizion B, Purmal A, Chapman J, Alford B. Inactivation of mycoplasma species in blood by INACTINE PEN110 process. Transfusion 2004; 44: 286-93.
31. Osselaer JC, Cazenave JP, Lambermont M, et al. An active haemovigilance programme characterizing the safety profile of 7437 platelet transfusions prepared with amotosalen photochemical treatment. Vox Sang 2008; 94: 315-23.
32. Irsch J, Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System™. Transfus Med Hemother 2011; 38: 19-31.
33. Picker SM, Speer R, Gathof BS. Evaluation of processing characteristics of photochemically treated pooled platelets: target requirements for the INTERCEPT Blood System comply with routine use after process optimization. Transfus Med 2004; 14: 217-23.
34. Seltsam A, Müller TH. UVC irradiation for pathogen reduction of platelet concentrates and plasma. Transfus Med Hemother 2011; 38: 43-54.
35. Steinmann E, Gravemann U, Friesland M, et al. Two pathogen reduction technologies-methylene blue plus light and shortwave ultraviolet light-effectively inactivate hepatitis C virus in blood products. Transfusion. 2012 Aug 21. doi: 10.1111/j.1537-2995.2012.03858.x. [Epub ahead of print].
36. Mohr H, Bachmann B, Klein-Struckmeier A, Lambrecht B. Virus inactivation of blood products by phenothiazine dyes and light. Photochem Photobiol 1997; 65: 441-5.
37. Mohr H, Steil L, Gravemann U, et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion. 2009; 49: 2612-24.
38. Verhaar R, Dekkers DW, De Cuyper IM, et al. UV-C irradiation disrupts platelet surface disulfide bonds and activates the platelet integrin alphaIIbbeta3. Blood 2008; 112: 4935-9; Erratum in: Blood 2009; 114: 1281.
39. Henschler R, Seifried E, Mufti N. Development of the S-303 pathogen inactivation technology for red blood cell concentrates. Transfus Med Hemother 2011; 38: 33-42.
40. Mufti NA, Erickson AC, North AK, et al. Treatment of whole blood (WB) and red blood cells (RBC) with S-303 inactivates pathogens and retains in vitro quality of stored RBC. Biologicals 2010; 38: 14-9.
41. Prowse C. Properties of pathogen-inactivated plasma components. Transfus Med Rev 2009; 23: 124-33.
42. Rock G. A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011; 100: 169-78.
43. Sandler SG. The status of pathogen-reduced plasma. Transfus Apher Sci 2010; 43: 393-9.
44. Seghatchian J, Struff WG, Reichenberg S. Main Properties of the THERAFLEX MB-Plasma System for pathogen reduction. Transfus Med Hemother 2011; 38: 55-64.
45. del Río-Garma J, Pereira A, Arroyo JL, et al; Spanish Group of Apheresis (Grupo Español de Aféresis GEA). ADAMTS-13 activity and von Willebrand factor levels in methylene-blue photo-inactivated plasma processed byeither the Springe method or an 'in house' system. Vox Sang 2008; 95: 101-5.
46. del Río-Garma J, Alvarez-Larrán A, Martínez C, et al. Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. Br J Haematol 2008; 143: 39-45.
47. Carlier M, Vo Mai MP, Fauveau L, et al. Seventeen years of haemovigilance in France: assessment and outlook. Transfus Clin Biol 2011; 18: 140-50.
48. Picker SM, Steisel A, Gathof BS. Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: Results of a three-arm in vitro study. Transfus Apher Sci 2009; 40: 79-85.
49. Picker SM, Oustianskaia L, Schneider V, Gathof BS. Functional characteristics of apheresis-derived platelets treated with ultraviolet light combined with either amotosalen-HCl (S-59) or riboflavin (vitamin B2) for pathogen-reduction. Vox Sang 2009; 97: 26-33.
50. Akkerman JW. Regulation of carbohydrate metabolism in platelets: a review. Thromb Haemost 1978; 39: 12-24.
51. Picker SM, Schneider V, Oustianskaia L, Gathof BS. Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies. Transfusion 2009; 49: 2311-8.
52. Picker SM, Schneider V, Gathof BS. Platelet function assessed by shear-induced deposition of split triple-dose apheresis concentrates treated with pathogen reduction technologies. Transfusion 2009; 49: 1224-32.
53. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004; 44: 877-85.
54. AuBuchon JP, Herschel L, Roger J et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005; 45: 1335-41.
55. Reikvam H, Marschner S, Apelseth TO, et al. The Mirasol pathogen reduction technology system and quality of platelets stored in platelet additive solution. Blood Transfus 2010; 8: 186-92.
56. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010; 50: 2362-75.
57. Lozano M, Galan A, Mazzara R, et al. Leukoreduced buffy coat-derived platelet concentrates photochemically treated with amotosalen HCl and ultraviolet A light stored up to 7 days: assessment of hemostatic function under flow conditions. Transfusion 2007; 47: 666-71.
58. Kerkhoffs JL, van Putten WL, Novotny VM, et al. Dutch - Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
59. Goodrich RP, Woolum A, Hansen E. Recovery and survival of radiolabelled platelets following treatment with a riboflavin based pathogen inactivation procedure. Blood 2001; 98: 541a.
60. Bashir S, Thomas S, Cardigan R, et al. Pathogen inactivation of platelets using UVC light. Transfus Med 2010; 20 (Suppl.1): 8.
61. North A, Propst M, Henschler R et al. Evolution of naturally occurring antibodies to pathogen inactivated red blood cells. Transfusion 2010; 50 (Suppl.): 38A.
62. North AK, Castro G, Erickson A, et al. Characterization of antibodies to red cells prepared with S-303 pathogen inactivation treatment. Vox Sang 2007; 93 (Suppl.1): 167-8.
63. Cancelas JA, Dumont LJ, Rugg N et al. Stored red blood cell viability is maintained after treatment with a secondgeneration S-303 pathogen inactivation process. Transfusion 2011; 51: 2367-76.
64. Bell C, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003; 25: 2464-86.
65. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-13.